Actuate Phase 2 pancreatic cancer trial meets OS endpoint; elraglusib+GnP reduces death risk 38%

ACTUATE THERAPEUTICS, INC.

Median OS 10.1 mo (elraglusib/GnP) vs 7.2 mo (GnP alone); HR=0.62, p=0.02.
12-month survival doubled: 44.4% vs 22.3%; 24-month survival fivefold: 12.9% vs 2.6%.
Safety profile consistent; serious TEAE 56.1% vs 56.4%; death-related TEAE 12.3% vs 16.7%.
Biomarker data suggest potential predictive value for KRAS, ARID1A; increased CD8+ and NK cells in combination arm.
Seventeen patients remain alive in elraglusib arm (3 >24 mo); none on GnP alone as of Nov 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.